BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 411 filers reported holding BIO-TECHNE CORP in Q3 2020. The put-call ratio across all filers is 1.11 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,617,832 | -15.8% | 155,984 | +1.0% | 0.92% | -11.1% |
| Q2 2023 | $12,607,426 | +19.0% | 154,446 | +8.1% | 1.04% | +8.0% |
| Q1 2023 | $10,597,152 | -4.4% | 142,838 | +6.8% | 0.96% | -10.8% |
| Q4 2022 | $11,089,343 | +20.1% | 133,800 | +311.6% | 1.08% | +12.1% |
| Q3 2022 | $9,232,000 | -19.2% | 32,509 | -1.4% | 0.96% | -16.9% |
| Q2 2022 | $11,430,000 | -20.6% | 32,975 | -0.8% | 1.16% | -7.9% |
| Q1 2022 | $14,398,000 | -16.6% | 33,249 | -0.3% | 1.26% | -13.0% |
| Q4 2021 | $17,255,000 | +1.2% | 33,353 | -5.2% | 1.45% | -8.4% |
| Q3 2021 | $17,053,000 | +1.5% | 35,194 | -5.7% | 1.58% | -1.2% |
| Q2 2021 | $16,796,000 | +14.2% | 37,303 | -3.1% | 1.60% | +9.0% |
| Q1 2021 | $14,706,000 | +12.9% | 38,506 | -6.1% | 1.47% | -3.0% |
| Q4 2020 | $13,029,000 | +27.7% | 41,029 | -0.4% | 1.51% | +11.2% |
| Q3 2020 | $10,200,000 | -6.1% | 41,177 | +0.1% | 1.36% | -10.5% |
| Q2 2020 | $10,859,000 | +37.8% | 41,123 | -1.0% | 1.52% | +14.4% |
| Q1 2020 | $7,879,000 | -13.1% | 41,550 | +0.6% | 1.33% | +9.7% |
| Q4 2019 | $9,062,000 | +11.4% | 41,285 | -0.7% | 1.21% | +1.1% |
| Q3 2019 | $8,138,000 | -6.9% | 41,590 | -0.8% | 1.20% | -11.3% |
| Q2 2019 | $8,744,000 | -0.3% | 41,940 | -5.1% | 1.35% | -1.5% |
| Q1 2019 | $8,773,000 | +34.3% | 44,186 | -2.1% | 1.37% | +18.8% |
| Q4 2018 | $6,532,000 | -29.6% | 45,131 | -0.7% | 1.15% | -19.8% |
| Q3 2018 | $9,279,000 | +33.6% | 45,460 | -3.1% | 1.44% | +19.1% |
| Q2 2018 | $6,944,000 | -3.9% | 46,936 | -1.9% | 1.21% | -9.2% |
| Q1 2018 | $7,228,000 | +14.7% | 47,856 | -1.6% | 1.33% | +14.4% |
| Q4 2017 | $6,301,000 | +7.2% | 48,636 | 0.0% | 1.16% | -0.5% |
| Q3 2017 | $5,880,000 | +2.3% | 48,636 | -0.6% | 1.17% | +2.0% |
| Q2 2017 | $5,749,000 | +15.3% | 48,926 | -0.3% | 1.15% | +12.9% |
| Q1 2017 | $4,988,000 | +0.0% | 49,076 | +1.2% | 1.02% | -10.6% |
| Q4 2016 | $4,987,000 | -6.5% | 48,496 | -0.4% | 1.14% | -7.0% |
| Q3 2016 | $5,331,000 | -5.4% | 48,686 | -2.6% | 1.22% | -5.4% |
| Q2 2016 | $5,636,000 | +20.7% | 49,986 | +1.1% | 1.29% | +10.2% |
| Q1 2016 | $4,671,000 | +4.4% | 49,421 | -0.6% | 1.17% | -0.8% |
| Q4 2015 | $4,473,000 | -1.6% | 49,696 | +1.1% | 1.18% | -7.5% |
| Q3 2015 | $4,544,000 | -9.2% | 49,146 | -3.3% | 1.28% | -0.3% |
| Q2 2015 | $5,003,000 | -1.3% | 50,811 | +0.5% | 1.28% | -0.2% |
| Q1 2015 | $5,069,000 | +19.0% | 50,541 | +9.6% | 1.28% | +17.0% |
| Q4 2014 | $4,259,000 | – | 46,096 | – | 1.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |